Citation: Tao Liu, Hui Zou, Jingqing Mu, Xi Zhang, Guohua Liu, Na Yu, Bo Yuan, Xiaoyong Yuan, Xingjie Liang, Shutao Guo. PDLLA length on anti-breast cancer efficacy of acid-responsive self-assembling mPEG-PDLLA‒docetaxel conjugates[J]. Chinese Chemical Letters, ;2023, 34(9): 108135. doi: 10.1016/j.cclet.2023.108135 shu

PDLLA length on anti-breast cancer efficacy of acid-responsive self-assembling mPEG-PDLLA‒docetaxel conjugates

Tao Liu ^{a, 1} ,
Hui Zou ^{a, 1} ,
Jingqing Mu ^a ,
Xi Zhang ^a ,
Guohua Liu ^a ,
Na Yu ^a ,
Bo Yuan ^b ,
Xiaoyong Yuan ^{b, c, d, *,} ,
Xingjie Liang ^e ,
Shutao Guo ^{a, *,}

a.
Key Laboratory of Functional Polymer Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin 300071, China
b.
School of Medicine, Nankai University, Tianjin 300071, China
c.
Clinical College of Ophthalmology, Tianjin Medical University, Tianjin 300020, China
d.
Tianjin Key Laboratory of Ophthalmology and Visual Science, Tianjin Eye Institute, Tianjin Eye Hospital, Tianjin 300020, China
e.
CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and National Center for Nanoscience and Technology of China, Beijing 100190, China

yuanxy_cn@hotmail.com

stguo@nankai.edu.cn

Received Date: 29 September 2022
Revised Date: 29 December 2022
Accepted Date: 3 January 2023
Available Online: 5 January 2023

Figures(4)

Engineering small-molecule drugs into nanoparticulate formulations provides an unprecedented opportunity to improve the performance of traditional chemo drugs, but suffers from poor compatibility between drugs and nanocarriers. Stimuli-responsive mPEG-PDLLA–drug conjugate-based nanomedicines can facilitate the exploitation of beneficial properties of the carrier and enable the practical fabrication of highly efficacious self-assembled nanomedicines. However, the influence of hydrophobic length on the performance of this type of nanomedicine is little known. Here we synthesized two acid-sensitive ketal-linked mPEG-PDLLA–docetaxel prodrugs with different lengths of PDLLA, and engineered them into self-assembled sub-20 nm micellar nanomedicines for breast cancer chemotherapy. We found that the nanomedicine consisting of a mPEG-PDLLA–docetaxel prodrug with the shorter length of PDLLA stood out due to its potent cytotoxicity, deep penetration into multicellular spheroids, and improved in vivo anticancer performance. Additionally, our prodrug-based nanomedicines outperformed the generic formulation of commercial Nanoxel in terms of safety profile, tolerated doses, and tumor suppression. Our findings indicate that the hydrophobic content of a polymeric prodrug nanomedicine plays an important role in the performance of the nanomedicine, and should be instructive for developing polymeric prodrug-based nanomedicines with clinical translational potential.
- Nanomedicine,
- Prodrug,
- Docetaxel,
- mPEG-PDLLA,
- Acid-sensitive
1. [1]
  J. Shi, P.W. Kantoff, R. Wooster, O.C. Farokhzad, Nat. Rev. Cancer 17 (2017) 20–37. doi: 10.1038/nrc.2016.108
2. [2]
  R. van der Meel, E. Sulheim, Y. Shi, et al., Nat. Nanotechnol. 14 (2019) 1007–1017. doi: 10.1038/s41565-019-0567-y
3. [3]
  W. Wang, Q. Liu, C. Zhan, et al., Nano Lett. 15 (2015) 6332–6338. doi: 10.1021/acs.nanolett.5b01325
4. [4]
  Y. Yuan, R. Bo, D. Jing, et al., Nano Res. 13 (2020) 503–510. doi: 10.1007/s12274-020-2641-z
5. [5]
  R.A. Petros, J.M. DeSimone, Nat. Rev. Drug Discov. 9 (2010) 615–627. doi: 10.1038/nrd2591
6. [6]
  B. Sun, R.M. Straubinger, J.F. Lovell, Nano Res. 11 (2018) 5193–5218. doi: 10.1007/s12274-018-2171-0
7. [7]
  F. Danhier, E. Ansorena, J.M. Silva, et al., J. Control. Release 161 (2012) 505–522.
8. [8]
  D. Hwang, J.D. Ramsey, A.V. Kabanov, Adv. Drug Deliv. Rev. 156 (2020) 80–118.
9. [9]
  Y. Zhao, F. Fay, S. Hak, et al., Nat. Commun. 7 (2016) 11221.
10. [10]
  J. Hrkach, D. Von Hoff, M.M. Ali, et al., Sci. Transl. Med. 4 (2012) 128ra139.
11. [11]
  L. Tan, J. Peng, Q. Zhao, et al., Theranostics 7 (2017) 2652–2672. doi: 10.7150/thno.19680
12. [12]
  S.Y. Lee, S. Kim, J.Y. Tyler, K. Park, J.X. Cheng, Biomaterials 34 (2013) 552–561. doi: 10.3341/jkos.2013.54.4.552
13. [13]
  P.M. Valencia, O.C. Farokhzad, R. Karnik, R. Langer, Nat. Nanotechnol. 7 (2012) 623–629. doi: 10.1038/nnano.2012.168
14. [14]
  I. Ekladious, Y.L. Colson, M.W. Grinstaff, Nat. Rev. Drug Discov. 18 (2019) 273–294. doi: 10.1038/s41573-018-0005-0
15. [15]
  Y. Shi, S. Kim, T.B. Huff, et al., Nat. Nanotechnol. 5 (2010) 80–87. doi: 10.1038/nnano.2009.303
16. [16]
  H.S. Yoo, T.G. Park, J. Control Release 96 (2004) 273–283.
17. [17]
  Q. Shuai, G. Zhao, X. Lian, et al., Int. J. Pharm. 574 (2020) 118879.
18. [18]
  L. Lu, Y. Zheng, S. Weng, et al., Colloids Surf. B 142 (2016) 417–423.
19. [19]
  N. Yu, Y. Xu, T. Liu, et al., Nat. Commun. 12 (2021) 5532.
20. [20]
  S.W. Lee, M.H. Yun, S.W. Jeong, et al., J. Control. Release 155 (2011) 262–271.
21. [21]
  K. Zhang, X. Tang, J. Zhang, et al., J. Control. Release 183 (2014) 77–86.
22. [22]
  T. Liu, H. Zou, J.Q. Mu, et al., Chin. Chem. Lett. 32 (2021) 1751–1754.
23. [23]
  D.E. Owens, 3rd, N.A. Peppas, Int. J. Pharm. 307 (2006) 93–102.
24. [24]
  T. Riley, C.R. Heald, S. Stolnik, et al., Langmuir 19 (2003) 8428–8435.
25. [25]
  J. Wang, W. Mao, L.L. Lock, et al., ACS Nano 9 (2015) 7195–7206. doi: 10.1021/acsnano.5b02017
26. [26]
  H. Cabral, Y. Matsumoto, K. Mizuno, et al., Nat. Nanotechnol. 6 (2011) 815–823. doi: 10.1038/nnano.2011.166
1. [1]
  Yunkang Tong , Haiqiao Huang , Haolan Li , Mingle Li , Wen Sun , Jianjun Du , Jiangli Fan , Lei Wang , Bin Liu , Xiaoqiang Chen , Xiaojun Peng . Cooperative bond scission by HRP/H₂O₂ for targeted prodrug activation. Chinese Chemical Letters, 2024, 35(12): 109663-. doi: 10.1016/j.cclet.2024.109663
2. [2]
  Zhongyu Wang , Lijun Wang , Huaixin Zhao . DNA-based nanosystems to generate reactive oxygen species for nanomedicine. Chinese Chemical Letters, 2024, 35(11): 109637-. doi: 10.1016/j.cclet.2024.109637
3. [3]
  Yating Zheng , Yulan Huang , Jing Luo , Xuqi Peng , Xiran Gui , Gang Liu , Yang Zhang . Supercritical fluid technology: A game-changer for biomacromolecular nanomedicine preparation and biomedical application. Chinese Chemical Letters, 2024, 35(7): 109169-. doi: 10.1016/j.cclet.2023.109169
4. [4]
  Zhi Li , Wenpei Li , Shaoping Jiang , Chuan Hu , Yuanyu Huang , Maxim Shevtsov , Huile Gao , Shaobo Ruan . Legumain-triggered aggregable gold nanoparticles for enhanced intratumoral retention. Chinese Chemical Letters, 2024, 35(7): 109150-. doi: 10.1016/j.cclet.2023.109150
5. [5]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
6. [6]
  Huijie An , Chen Yang , Zhihui Jiang , Junjie Yuan , Zhongming Qiu , Longhao Chen , Xin Chen , Mutu Huang , Linlang Huang , Hongju Lin , Biao Cheng , Hongjiang Liu , Zhiqiang Yu . Luminescence-activated Pt(Ⅳ) prodrug for in situ triggerable cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109134-. doi: 10.1016/j.cclet.2023.109134
7. [7]
  Keyang Li , Yanan Wang , Yatao Xu , Guohua Shi , Sixian Wei , Xue Zhang , Baomei Zhang , Qiang Jia , Huanhua Xu , Liangmin Yu , Jun Wu , Zhiyu He . Flash nanocomplexation (FNC): A new microvolume mixing method for nanomedicine formulation. Chinese Chemical Letters, 2024, 35(10): 109511-. doi: 10.1016/j.cclet.2024.109511
8. [8]
  Lin Li , Bingjun Sun , Jin Sun , Lin Chen , Zhonggui He . Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy. Chinese Chemical Letters, 2024, 35(10): 109538-. doi: 10.1016/j.cclet.2024.109538
9. [9]
  Hao Sun , Shengke Li , Qian Liu , Minzan Zuo , Xueqi Tian , Kaiya Wang , Xiao-Yu Hu . Supramolecular prodrug vesicles for selective antimicrobial therapy employing a chemo-photodynamic strategy. Chinese Chemical Letters, 2025, 36(3): 109999-. doi: 10.1016/j.cclet.2024.109999
10. [10]
  Huijiao Fu , Peiqin Liang , Qianwen Chen , Yan Wang , Guang Li , Xuzi Cai , Shengtao Wang , Kun Chen , Shengying Shi , Zhiqiang Yu , Xuefeng Wang . COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer: An allicin-based nanomedicine approach. Chinese Chemical Letters, 2024, 35(8): 109241-. doi: 10.1016/j.cclet.2023.109241
11. [11]
  An Lu , Yuhao Guo , Yi Yan , Lin Zhai , Xiangyu Wang , Weiran Cao , Zijie Li , Zhixia Zhao , Yujie Shi , Yuanjun Zhu , Xiaoyan Liu , Huining He , Zhiyu Wang , Jian-Cheng Wang . Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy. Chinese Chemical Letters, 2024, 35(6): 108928-. doi: 10.1016/j.cclet.2023.108928
12. [12]
  Yuanyi Zhou , Ke Ma , Jinfeng Liu , Zirun Zheng , Bo Hu , Yu Meng , Zhizhong Li , Mingshan Zhu . Is reactive oxygen species the only way for cancer inhibition over single atom nanomedicine? Autophagy regulation also works. Chinese Chemical Letters, 2024, 35(6): 109056-. doi: 10.1016/j.cclet.2023.109056
13. [13]
  Wenjia Wang , Xingyue He , Xiaojie Wang , Tiantian Zhao , Osamu Muraoka , Genzoh Tanabe , Weijia Xie , Tianjiao Zhou , Lei Xing , Qingri Jin , Hulin Jiang . Glutathione-depleted cyclodextrin pseudo-polyrotaxane nanoparticles for anti-inflammatory oxaliplatin (Ⅳ) prodrug delivery and enhanced colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(4): 108656-. doi: 10.1016/j.cclet.2023.108656
14. [14]
  Jiaqi Huang , Renjiang Kong , Yanmei Li , Ni Yan , Yeyang Wu , Ziwen Qiu , Zhenming Lu , Xiaona Rao , Shiying Li , Hong Cheng . Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs. Chinese Chemical Letters, 2024, 35(8): 109254-. doi: 10.1016/j.cclet.2023.109254
15. [15]
  Ying Wang , Hong Yang , Caixia Zhu , Qing Hong , Xuwen Cao , Kaiyuan Wang , Yuan Xu , Yanfei Shen , Songqin Liu , Yuanjian Zhang . Cascading oxidoreductases-like nanozymes for high selective and sensitive fluorescent detection of ascorbic acid. Chinese Chemical Letters, 2025, 36(4): 110153-. doi: 10.1016/j.cclet.2024.110153
16. [16]
  Jie ZHANG , Xin LIU , Zhixin LI , Yuting PEI , Yuqi YANG , Huimin LI , Zhiqiang LIU . Assembling a luminescence silencing system based on post-synthetic modification strategy: A highly sensitive and selective turn-on metal-organic framework probe for ascorbic acid detection. Chinese Journal of Inorganic Chemistry, 2024, 40(4): 823-833. doi: 10.11862/CJIC.20230310
17. [17]
  Jing Guo , Zhi-Guo Lu , Rui-Chen Zhao , Bao-Ku Li , Xin Zhang . Nucleic acid therapy for metabolic-related diseases. Chinese Chemical Letters, 2025, 36(3): 109875-. doi: 10.1016/j.cclet.2024.109875
18. [18]
  Wenyi Mei , Lijuan Xie , Xiaodong Zhang , Cunjian Shi , Fengzhi Wang , Qiqi Fu , Zhenjiang Zhao , Honglin Li , Yufang Xu , Zhuo Chen . Design, synthesis and biological evaluation of fluorescent derivatives of ursolic acid in living cells. Chinese Chemical Letters, 2024, 35(5): 108825-. doi: 10.1016/j.cclet.2023.108825
19. [19]
  Huipeng Zhao , Xiaoqiang Du . Polyoxometalates as the redox anolyte for efficient conversion of biomass to formic acid. Chinese Journal of Structural Chemistry, 2024, 43(2): 100246-100246. doi: 10.1016/j.cjsc.2024.100246
20. [20]
  Dan-Ying Xing , Xiao-Dan Zhao , Chuan-Shu He , Bo Lai . Kinetic study and DFT calculation on the tetracycline abatement by peracetic acid. Chinese Chemical Letters, 2024, 35(9): 109436-. doi: 10.1016/j.cclet.2023.109436

Get Citation

PDF

XML

Metrics

PDF Downloads(4)
Abstract views(319)
HTML views(2)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142